Matthias Scheffler (Mathias Hoiczyk)

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 16

Top Topics

Advanced Non Small Cell Lung Cancer

Clinical Practice

Epidermal Growth Factor Receptor

Small Cell Lung Cancer

Top Venues

JCO precision oncology

Advances in therapy

Clinical cancer research : an official journal of the American Association for Cancer Research

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Theresa Reutter, Jana Fassunke, Michael Püsken, Jan-Phillip Weber, Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogova, Richard Riedel, Diana Schaufler, Heather Scharpenseel, Matthias Scheffler, Holger Schulz, Dirk-Thomas Waldschmidt, Thomas Zander, Sabine Merkelbach-Bruse, Peter Schirmacher, Reinhard Buttner, Juergen Wolf, Sebastian Michels
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report. JCO precision oncology 7 (2023)
Julia Rotow, Jyoti D Patel, Matthew P Hanley, Helena Alexandra Yu, Mark M Awad, Jonathan Wade Goldman, Hovav Nechushtan, Matthias Scheffler, Allen Chung-Cheng Huang, Senthil Rajappa, Guilherme Harada, Sarah Clifford, Alison D Santucci, Laura Silva, Rebecca Tupper, Geoffrey R Oxnard, Jennifer Kherani, Alexander E Drilon
Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Theresa Reutter, Jana Fassunke, Michael Püsken, Jan-Phillip Weber, Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogova, Richard Riedel, Diana Schaufler, Heather Scharpenseel, Matthias Scheffler, Holger Schulz, Dirk-Thomas Waldschmidt, Thomas Zander, Sabine Merkelbach-Bruse, Peter Schirmacher, Reinhard Buttner, Juergen Wolf, Sebastian Michels
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report. JCO precision oncology 7 (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Theresa Reutter, Jana Fassunke, Michael Püsken, Jan-Phillip Weber, Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogova, Richard Riedel, Diana Schaufler, Heather Scharpenseel, Matthias Scheffler, Holger Schulz, Dirk-Thomas Waldschmidt, Thomas Zander, Sabine Merkelbach-Bruse, Peter Schirmacher, Reinhard Buttner, Juergen Wolf, Sebastian Michels
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report. JCO precision oncology 7 (2023)
Theresa Reutter, Jana Fassunke, Michael Püsken, Jan-Phillip Weber, Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogova, Richard Riedel, Diana Schaufler, Heather Scharpenseel, Matthias Scheffler, Holger Schulz, Dirk-Thomas Waldschmidt, Thomas Zander, Sabine Merkelbach-Bruse, Peter Schirmacher, Reinhard Buttner, Juergen Wolf, Sebastian Michels
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report. JCO precision oncology 7 (2023)
Marcelo Vailati Negrão, Haniel A Araujo, Giuseppe Lamberti, Alissa J Cooper, Neal S Akhave, Teng Zhou, Lukas Delasos, J Kevin Hicks, Mihaela Aldea, Gabriele Minuti, Jacobi Hines, Jacqueline V Aredo, Michael J Dennis, Turja Chakrabarti, Susan C Scott, Paolo Bironzo, Matthias Scheffler, Petros Christopoulos, Albrecht Stenzinger, Jonathan W Riess, So Yeon Kim, Sarah B Goldberg, Mingjia Li, Qi Wang, Yun Qing, Ying Ni, Minh Truong Do, Richard Lee, Biagio Ricciuti, Joao M Victor Alessi, Jing Wang, Blerina Resuli, Lorenza Landi, Shu-Chi Tseng, Mizuki Nishino, Subba R Digumarthy, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Ara A Vaporciyan, George R Blumenschein, Jianjun Zhang, Dwight H Owen, Collin M Blakely, Giannis S Mountzios, Catherine A Shu, Christine M Bestvina, Marina-Chiara Garassino, Kristen A Marrone, Jhanelle E Gray, Sandip Pravin Patel, Amy L Cummings, Heather A Wakelee, Juergen Wolf, Giorgio Vittorio Scagliotti, Federico Cappuzzo, Fabrice Barlesi, Pradnya D Patil, Leylah Drusbosky, Don L Gibbons, Funda Meric-Bernstam, Jiun-Kae Jack Lee, John Victor Heymach, David S Hong, Rebecca S Heist, Mark M Awad, Ferdinandos Skoulidis
Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer discovery (2023)
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig S Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J Perualila, Claudio A Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in therapy 40 (3) (2023)
Theresa Reutter, Jana Fassunke, Michael Püsken, Jan-Phillip Weber, Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogova, Richard Riedel, Diana Schaufler, Heather Scharpenseel, Matthias Scheffler, Holger Schulz, Dirk-Thomas Waldschmidt, Thomas Zander, Sabine Merkelbach-Bruse, Peter Schirmacher, Reinhard Buttner, Juergen Wolf, Sebastian Michels
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report. JCO precision oncology 7 (2023)
Martin Metzenmacher, Filippo Rizzo, Kato Kambartel, Jens Peter Panse, Diana Schaufler, Matthias Scheffler, Ivo Azeh, Matthias Scheffler, Amin T Turki, Judith Atz, Hannes Buchner, Christopher M Hoffmann, Daniel C Christoph
Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. Future oncology (London, England) 17 (30) (2021)
Diana Schaufler, David F Ast, Hannah L Tumbrink, Nima Abedpour, Lukas Maas, Ayla E Schwäbe, Inga Spille, Stefanie Lennartz, Jana Fassunke, Mihaela Aldea, Benjamin Besse, David Planchard, Lucia Nogova, Sebastian Michels, Carsten Kobe, Thorsten Persigehl, Theresa Westphal, Sophia Koleczko, Rieke Fischer, Jan-Phillip Weber, Janine Altmüller, Roman K Thomas, Sabine Merkelbach-Bruse, Oliver Gautschi, Laura Mezquita, Reinhard Buttner, Jürgen Wolf, Martin Peifer, Johannes Brägelmann, Matthias Scheffler, Martin L Sos
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. NPJ precision oncology 5 (1) (2021)
Lucia Nogova, Christian Mattonet, Matthias Scheffler, Max Taubert, Masyar Gardizi, Martin L Sos, Sebastian Michels, Rieke N Fischer, Meike Limburg, Diana S Y Abdulla, Thorsten Persigehl, Carsten Kobe, Sabine Merkelbach-Bruse, Jeremy Franklin, Heiko Backes, Roland Schnell, Dirk Behringer, Britta Kaminsky, Martina Eichstaedt, Christoph Stelzer, Martina Kinzig, Fritz Sörgel, Yingying Tian, Lisa Junge, Ahmed A Suleiman, Sebastian Frechen, Dennis Rokitta, Dongsheng Ouyang, Uwe Fuhr, Reinhard Buettner, Jürgen Wolf
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. Cancer medicine 9 (14) (2020)
Rieke Frank, Matthias Scheffler, Sabine Merkelbach-Bruse, Michaela A Ihle, Anna Kron, Michael Rauer, Frank Ueckeroth, Katharina König, Sebastian Michels, Rieke Fischer, Anna Eisert, Jana Fassunke, Carina Heydt, Monika Serke, Yon-Dschun Ko, Ulrich Gerigk, Thomas Geist, Britta Kaminsky, Lukas C Heukamp, Mathieu Clement-Ziza, Reinhard Büttner, Jürgen Wolf
Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC). Clinical cancer research : an official journal of the American Association for Cancer Research 24 (13) (2018)